These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23111661)

  • 1. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
    Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
    Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
    [No Abstract]   [Full Text] [Related]  

  • 2. Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
    Singh SN; Cao Q; Gojo I; Rapoport AP; Akpek G
    Bone Marrow Transplant; 2012 Jul; 47(7):1008-9. PubMed ID: 22080965
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of decitabine with allogeneic progenitor cell transplantation.
    Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
    Leukemia; 1997 Mar; 11 Suppl 1():S32-4. PubMed ID: 9130690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation.
    Ustun C; Kalla A; Farrow S; DeRemer DL; Jillella A
    Am J Hematol; 2008 Oct; 83(10):825-7. PubMed ID: 18767131
    [No Abstract]   [Full Text] [Related]  

  • 6. Decitabine treatment for acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation.
    Liu XL; Zhao X; Wang C; Gao SJ; Tan YH
    J Biol Regul Homeost Agents; 2017; 31(1):171-175. PubMed ID: 28337888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
    Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Decitabine Combined with Unrelated Cord Blood Transplantation in an Adult Patient with -7/EVI1+ Acute Myeloid Leukemia: a Case Report and Literature Review.
    Jiang YZ; Su GP; Dai Y; He HS; Huang LQ; Sun ZM; Huang DP
    Ann Clin Lab Sci; 2015; 45(5):598-601. PubMed ID: 26586716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
    Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G
    Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
    Lübbert M; Bertz H; Rüter B; Marks R; Claus R; Wäsch R; Finke J
    Bone Marrow Transplant; 2009 Nov; 44(9):585-8. PubMed ID: 19363531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
    Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
    Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful azacitidine treatment with increase of regulatory T cells for relapsed acute myeloid leukemia after allogeneic stem cell transplant.
    Yamamoto W; Tachibana T; Ogusa E; Matsumoto K; Maruta A; Ishigatsubo Y; Kanamori H
    Leuk Lymphoma; 2013 Sep; 54(9):2079-80. PubMed ID: 23297798
    [No Abstract]   [Full Text] [Related]  

  • 15. Decitabine+ CAG +DLI in relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Wang B; Jin X; Wang Q; Jing Y
    J BUON; 2016; 21(1):280-1. PubMed ID: 27061561
    [No Abstract]   [Full Text] [Related]  

  • 16. Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia.
    Zhang C; Chen XH; Liu J; Gao L; Liu Y; Gao L; Kong PY; Zhang X
    J Clin Pharm Ther; 2015 Jun; 40(3):336-8. PubMed ID: 25825260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.
    Cahu X; Mohty M; Faucher C; Chevalier P; Vey N; El-Cheikh J; Guillaume T; Furst S; Delaunay J; Ayari S; Moreau P; Gastaut JA; Harousseau JL; Blaise D
    Bone Marrow Transplant; 2008 Nov; 42(10):689-91. PubMed ID: 18679370
    [No Abstract]   [Full Text] [Related]  

  • 18. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
    Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
    Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
    Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
    Craddock C; Jilani N; Siddique S; Yap C; Khan J; Nagra S; Ward J; Ferguson P; Hazlewood P; Buka R; Vyas P; Goodyear O; Tholouli E; Crawley C; Russell N; Byrne J; Malladi R; Snowden J; Dennis M
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):385-390. PubMed ID: 26363443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.